Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag teclistamab

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

AUGUST 25, 2022

Tecvayli (teclistamab) has been approved by the European Commission for adults with the blood cancer whose disease has progressed have after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, said J&J. and 18,3 months, respectively.

FDA

FDA Marketing Safety Patients

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

pharmaphorum

JULY 25, 2022

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J’s myeloma therapy portfolio alongside Darzalex (daratumumab) – an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). .”

Medicine

Medicine FDA Recruitment Patients

J&J gets first approval for multiple myeloma bispecific Tecvayli

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

Stay Connected